Effects of peridialytic oral supplements on nutritional status and quality of life in chronic hemodialysis patients.
OBJECTIVE
Our objective was to determine the effects of peridialytic oral supplements on nutritional markers and quality of life (QOL) in patients receiving maintenance hemodialysis.


METHODS
This trial was open, prospective, nonrandomized, and comparative.


METHODS
This study was performed at an outpatient hemodialysis unit in a teaching hospital.


METHODS
This study included 88 adults with chronic kidney disease at stage 5.


METHODS
This study involved directly observed nutrition therapy with >or=1 can of enteral nutrition (Nepro) with each hemodialysis session thrice weekly for 3 months, or standard care.


METHODS
Changes in biochemical markers of nutritional status and QOL, as measured by the Kidney Disease Quality of Life-Short Form, were determined.


RESULTS
Peridialytic oral nutrition resulted in a significant difference between the nutrition and comparison groups in serum albumin change over time (P = .03; repeated-measures analysis of variance with covariates). Mean (+/-SD) serum albumin concentration did not differ between baseline and month 3 in the nutrition group (3.68 +/- 0.33 g/dL vs. 3.75 +/- 0.40 g/dL; P = .12), but in the comparison group, serum albumin levels declined significantly (3.93 +/- 0.34 g/dL at baseline versus 3.81 +/- 0.37 g/dL at month 3; P = .04). The "role-physical" domain score of the Kidney Disease Quality of Life-Short Form significantly changed over time in the nutrition group versus the comparison group (P = .02; repeated-measures analysis of variance with covariates). Nepro was well-tolerated, and greater than 80% of the prescribed therapy was consumed.


CONCLUSIONS
Oral nutrition, as part of structured, directly observed peridialytic therapy in chronic hemodialysis patients, was well-accepted, and resulted in the maintenance of serum albumin levels and QOL with respect to impact of physical health on daily activities. These findings need to be confirmed in a randomized, controlled trial.
Scott
Meri Kay
MK
Clinical Development Organization, Eli Lilly and Co, Indianapolis, Indiana.
Shah
Niyati A
NA
Vilay
A Mary
AM
Thomas
Joseph
J
Kraus
Michael A
MA
Mueller
Bruce A
BA
D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D004750:Enteral Nutrition / Q000379:methods*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000523:psychology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009748:Nutrition Disorders / Q000097:blood / Q000517:prevention & control; D009752:Nutritional Status; D011446:Prospective Studies; D011788:Quality of Life; D006435:Renal Dialysis; D012709:Serum Albumin / Q000032:analysis; D011795:Surveys and Questionnaires
D015415:Biomarkers; D012709:Serum Albumin